Treatment of @entity1534 @entity3621 : a pilot study using @entity4140 ( @entity4140 ) and three formulations of colloidal @entity26586 ( XXXX ).

@entity1 @entity1066 @entity26586 @entity3621 @entity1534 @entity4140
Antral biopsies were obtained to detect @entity1534 infection in 382 @entity1 referred for gastroscopy. One hundred and seventy four @entity1 (46%) were infected. Infection was strongly associated with histological @entity3621 (p less than 0.001), but there was no association between histological antral @entity3621 and the appearance of the gastric antrum during gastroscopy. Because it has been suggested that the lower relapse rate for duodenal @entity1066 following colloidal @entity26586 (CBS) is due to suppression of @entity1534 we investigated different formulations and dosing of CBS for their efficacy in clearing @entity1534 . Seventy four infected @entity1 were prospectively assigned to therapy with @entity4140 (11 @entity1 ) or one of four regimens of CBS; one swallow tablet 4 times a day (11 @entity1 ); two swallow tablets twice daily (16 @entity1 ); two buffered swallow tablets twice daily (14 @entity1 ); or two chew tablets twice daily (22 @entity1 ). All @entity1 treated with @entity4140 and one CBS swallow tablet 4 times a day were still infected after treatment. Infection was not detected in 16 @entity1 taking twice daily doses of CBS; 8 (50%), 3 (21%) and 5 (23%) @entity1 taking two standard, buffered or chew tabs twice daily respectively. Improvement of histological @entity3621 was observed only in those @entity1 apparently cleared of @entity1534 (p less than 0.01) and this was due to a decrease in polymorphonuclear leukocytes. Nine @entity1 apparently cleared of the infection were rebiopsied 44-137 days following treatment and 6 (66%) were found again to be infected. This study suggests that suppression of @entity1534 may vary with the formulation and dosing of CBS.(ABSTRACT TRUNCATED AT 250 WORDS)
